X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IRX-2 is a primary cell-derived multi-cytokine biologic immunotherapy in development for multiple solid tumor indications. IRX-2 is administered locally by subcutaneous injection and is designed to activate T cells to generate an anti-tumor response.
Lead Product(s): IRX-2,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: IRX-2
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The Company intends to use the funds to commence translation of the gene editing, cellular therapy and nanolipid particle platform into its clinical programs with a focus on orphan diseases, like sickle cell anemia, familial amyloidosis and cell therapies for cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 24, 2021
Details:
The deal would allow Brooklyn to utilize an extensively patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, non-immunogenic and non-mutagenic, for treatment of several solid tumor and liquid indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Factor Bioscience
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2021
Details:
Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the treatment of cancer.
Lead Product(s): IRX-2,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: IRX-2
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NTN Buzztime
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Merger August 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
